Epidermal growth factor receptor 2 (HER2, neu, erbb2) is commonly over-expressed in human breast cancer and is a druggable target, with trastuzumab (Herceptin®, Genentech) improving outcome in women with HER2-expressing breast cancer [85]. This evidence concerns the gene ERBB2 and breast carcinoma.